

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF ILLINOIS
EASTERN DIVISION**

IN RE: HAIR RELAXER MARKETING
SALES PRACTICES AND PRODUCTS
LIABILITY LITIGATION

MDL No. 3060

Master Docket No. 1:23-cv-00818

Hon. Mary M. Rowland

**L'ORÉAL USA'S UNOPPOSED MOTION FOR ISSUANCE OF SUPPLEMENTAL
REQUEST FOR INTERNATIONAL JUDICIAL ASSISTANCE, APPOINTMENT OF
COMMISSIONER AND DIRECTION OF SUBMISSION OF HAGUE CONVENTION
APPLICATION**

Pursuant to the Court's Orders dated December 27, 2023 (ECF No. 353) and March 4, 2024 (ECF No. 499) regarding Plaintiffs' request for documents maintained by L'Oréal S.A.; directions from Special Master Grossman, including those provided during the January 9, 2025, conference between Plaintiffs, L'Oréal USA, Inc. and L'Oréal S.A.; and the parties' discussions and agreements regarding Plaintiffs' request for additional documents maintained by L'Oréal S.A., the French parent company of Defendants L'Oréal USA, Inc., L'Oréal USA Products, Inc. and SoftSheen-Carson LLC (collectively, "L'Oréal USA"), L'Oréal USA hereby moves, unopposed, for an Order:

1. Issuing a Supplemental Request for International Judicial Assistance ("Request for Assistance") pursuant to 28 U.S.C. § 1781 and Chapter II of the Hague Convention on the Taking of Evidence Abroad in Civil Commercial Matters, March 18, 1970, T.I.A.S. No. 7444, 28 U.S.T. 2555 (the "Hague Convention") in the form annexed as **Exhibit A** to the

Supplemental Declaration of Dennis S. Ellis (“Supplemental Ellis Declaration”), filed concurrently herewith;

2. Expanding the scope of Ms. Noëlle Lenoir’s appointment as commissioner (“Commissioner”) pursuant to Article 17 of the Hague Convention, pending the approval of the French Ministère de la Justice, to (a) receive additional documents from L’Oréal S.A. that are responsive to Plaintiffs’ Requests for Production of Documents directed to L’Oréal USA and that Plaintiffs, L’Oréal USA, and L’Oréal S.A. have stipulated will be produced (to the extent they exist), which consist of the categories of documents set forth in Exhibit 1 to the Supplemental Letter of Request (collectively, the “Supplemental Documents”); (b) transmit the Supplemental Documents to L’Oréal USA for review and production in this action pursuant to Article 17 of the Hague Convention and in performance of her appointment as Commissioner and duties thereunder; and (c) upon completion to inform the French Ministère de la Justice;
3. Directing submission of the Order and Supplemental Request for Assistance to the French Ministère de la Justice, for the purpose of approving the appointment of the Commissioner;
4. Granting the additional relief set forth in the Proposed Order attached as **Exhibit B** to the Supplemental Ellis Declaration; and
5. Granting such other and further relief as this Court may deem just and proper.

A Proposed Order is annexed as Exhibit B to the Supplemental Ellis Declaration. As is reflected in the Supplemental Ellis Declaration, Plaintiffs do not oppose this motion.

Dated: April 4, 2025

By: /s/ Dennis S. Ellis

Dennis S. Ellis
Katherine F. Murray
Noah S. Helpern
Serli Polatoglu
ELLIS GEORGE LLP
2121 Avenue of the Stars, 30th Floor
Los Angeles, CA 90067
T: (310) 274-7100
F: (310) 275-5697
dellis@ellisgeorge.com
kmurray@ellisgeorge.com
nhelpern@ellisgeorge.com
spolatoglu@ellisgeorge.com

Jonathan Blakley (6308603)
Gordon Rees Scully Mansukhani LLP
1 N. Franklin St., Suite 800
Chicago, IL 60606
T: (312) 565-1400
F: (312) 565-6511
jblakley@grsm.com

Peter Siachos (68465)
Gordon Rees Scully Mansukhani LLP
18 Columbia Turnpike, Suite 220
Florham Park, NJ 07932
T: (973) 549-2500
F: (973) 377-1911
psiachos@grsm.com

*Counsel for Defendants L'Oréal USA, Inc.;
L'Oréal USA Products, Inc.; and SoftSheen-
Carson LLC*

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF ILLINOIS
EASTERN DIVISION**

IN RE: HAIR RELAXER MARKETING
SALES PRACTICES AND PRODUCTS
LIABILITY LITIGATION

MDL No. 3060

Master Docket No. 1:23-cv-00818

Hon. Mary M. Rowland

**SUPPLEMENTAL DECLARATION OF DENNIS S. ELLIS IN SUPPORT OF L'ORÉAL
USA'S UNOPPOSED MOTION FOR ISSUANCE OF SUPPLEMENTAL REQUEST
FOR INTERNATIONAL JUDICIAL ASSISTANCE, APPOINTMENT OF
COMMISSIONER AND DIRECTION OF SUBMISSION OF HAGUE CONVENTION
APPLICATION**

Pursuant to 28 U.S.C. § 1746, Dennis S. Ellis hereby declares:

1. I am a member in good standing of the bar of this Court and a partner with the law firm of Ellis George LLP, counsel for Defendants L'Oréal USA, Inc., L'Oréal USA Products, Inc. and SoftSheen-Carson LLC (collectively, "L'Oréal USA") in the above-captioned action. I submit this declaration in support of L'Oréal USA's Unopposed Motion for Issuance of Supplemental Request for International Judicial Assistance, Appointment of Commissioner and Direction of Submission of Hague Convention Application (the "Motion").

2. Plaintiffs have reviewed and do not oppose the Motion.

3. L'Oréal USA respectfully requests that the Court enter the Proposed Order in the form annexed hereto as **Exhibit B**:

- a. Issuing a Supplemental Request for International Judicial Assistance in the Authorization of a Commissioner ("Request for Assistance") pursuant to 28 U.S.C. § 1781 and Chapter II of the Hague Convention on the Taking of Evidence Abroad in Civil or Commercial Matters, March 18, 1970,

T.I.A.S. No. 7444, 28 U.S.T. 2555 (the “Hague Convention”) in the form annexed hereto as **Exhibit A**;

- b. Appointing Ms. Noëlle Lenoir as commissioner (“Commissioner”) and/or expanding Ms. Lenoir’s existing role as Commissioner pursuant to Article 17 of the Hague Convention, pending the approval of the French Ministère de la Justice, to (a) receive additional documents from L’Oréal S.A. that are responsive to Plaintiffs’ Requests for Production of Documents to L’Oréal USA and that Plaintiffs, L’Oréal USA, and L’Oréal S.A. have stipulated will be produced (to the extent they exist), which consist of the categories of documents set forth in Exhibit 1 to the Supplemental Letter of Request (collectively, the “Supplemental Documents”), (b) transmit the Supplemental Documents to L’Oréal USA for review and production in this action pursuant to Article 17 of the Hague Convention and in performance of her appointment as Commissioner and duties thereunder; and (c) upon completion to inform the French Ministère de la Justice;
- c. Directing submission of the Order and Supplemental Request for Assistance to the French Ministère de la Justice, for the purpose of approving the appointment of the Commissioner;
- d. Granting the additional relief set forth in the Proposed Order attached as Exhibit B to the Ellis Declaration; and
- e. Granting such other and further relief as this Court may deem just and proper.

Summary of Case

4. On or around October 21, 2022, Plaintiffs began filing lawsuits across the country against manufacturers of hair relaxer products, including L'Oréal USA. On February 6, 2023, the Judicial Panel on Multidistrict Litigation created this MDL and assigned all of the federal cases to this Court.

5. On May 15, 2023, Plaintiffs filed a Master Long Form Personal Injury Complaint in the MDL (ECF No. 106), alleging that their regular and prolonged exposure to Defendants' hair relaxer products caused them to develop injuries, including uterine and ovarian cancer and other injuries. Based on these allegations, Plaintiffs asserted personal injury, wrongful death, misrepresentation, fraud, and consumer protection claims. The Defendants filed a motion to dismiss the Master Long Form Complaint. (ECF No. 142.) The Court granted the motion, in part, dismissing the fraud-based claims and denying the balance of the motion, allowing Plaintiffs to proceed with their products liability claims. (ECF No. 291.)

6. On December 5, 2024, the Court granted L'Oréal USA's Unopposed Motion for Issuance of a Letter of Request (ECF No. 973), finding it proper to issue a Request for International Judicial Assistance to authorize a commissioner in France to assist in the process of obtaining certain documents from France that are responsive to discovery served by Plaintiffs in this action and subject to orders of this Court. Also on December 5, the Court issued a Letter of Request to the French Ministère de la Justice (ECF No. 974).

7. On December 17, 2024, the French Ministère de la Justice appointed Ms. Noëlle Lenoir as Commissioner in connection with the review of certain categories of documents previously ordered by this Court to be produced from L'Oréal S.A. Ms. Noëlle Lenoir is an attorney resident in Paris, France and a member of the Paris bar. Ms. Noëlle Lenoir has no prior

affiliation with L'Oréal S.A. or L'Oréal USA, except as to her role as Commissioner in connection with this proceeding.

8. Since that time, L'Oréal USA has produced documents in connection with the prior Letter of Request and the Plaintiffs, L'Oréal USA, and L'Oréal S.A. have met and conferred regarding the appropriate scope of discovery and additional documents (to the extent they exist) that Plaintiffs seek in the possession of L'Oréal S.A., including through conferences with the Special Master appointed by the Court in this action to assist in resolution of discovery disputes. As a result of this process, Plaintiffs, L'Oréal USA, and L'Oréal S.A. have agreed that additional categories of documents responsive to discovery requests served on L'Oréal USA shall be obtained and produced from L'Oréal S.A., i.e., the Supplemental Documents.

9. The Parties have agreed to channel production of the Supplemental Documents through the Hague Convention consent procedures, which will allow for the Supplemental Documents to be produced more quickly than if the parties were to pursue the documents through the letter of request procedure.

10. L'Oréal USA and Plaintiffs agree to use Ms. Lenior as Commissioner with respect to the Supplemental Documents in view of her prior appointment and familiarity with these proceedings.

11. Upon issuance of the Supplemental Request for International Judicial Assistance and endorsement of the Proposed Order by this Court, Ellis George LLP, counsel for L'Oréal USA, will file or request the Commissioner to file both documents (and any exhibits thereto), along with French translations of these documents (and any exhibits thereto), with the Ministère de la Justice Direction des Affaires Civiles et du Sceau, Bureau de l'entraide civile et commerciale internationale (D3), 13, Place Vendôme, 75042 Paris Cedex 01, France. Upon

approval of the Commissioner by the Ministère de la Justice, L'Oréal S.A. can begin transmission of the Supplemental Documents to the Commissioner.

12. To expedite the process, the attached Supplemental Request for Assistance contains paragraph 3 stating that the Commissioner has been designated to accept service of the Hague Convention authorization and notifications from French governmental authorities related to the Hague Convention proceedings and to transmit the authorization and notifications to counsel for L'Oréal USA.

13. Additional terms of the agreement between L'Oréal USA and Plaintiffs, including as to timing and scope of the production, are reflected in the Supplemental Request for Assistance and the Proposed Order, attached hereto as Exhibits A and B, respectively.

14. The Parties have agreed that all costs of this Hague Convention process, including, without limitation, the fees of the Commissioner, translation fees for these motion papers, and any transmittal costs for the Supplemental Documents, will be borne by L'Oréal USA. Each party will be responsible for the fees and expenses, if any, of its own attorneys relating to any proceedings arising from this Hague Convention process.

15. The Parties have explicitly reserved their rights with respect to this Motion and discovery generally. For avoidance of all doubt, neither this Motion, the Proposed Order, the transmission of Supplemental Documents by L'Oréal S.A. to the Commissioner pursuant to the Hague Convention, nor the terms of the Supplemental Request for Assistance (which are incorporated into the Proposed Order) shall constitute or operate as a waiver of any argument, position, objection, allegation or claim or defense of Plaintiffs or L'Oréal USA, or any defense to personal jurisdiction that L'Oréal S.A. may otherwise have, or of the attorney-client privilege, the work product doctrine, or any other privileges, rights, protections or prohibitions that may

apply to that evidence under the law of France, the United States, or the State of Illinois. All materials withheld, in whole or in part, on the basis of attorney-client privilege shall be so identified on an appropriate log in accordance with Federal Rule of Civil Procedure 26(b)(5).

Dated: April 4, 2025

By: /s/ Dennis S. Ellis

Dennis S. Ellis

ELLIS GEORGE LLP

2121 Avenue of the Stars, 30th Floor

Los Angeles, California 90067

Telephone: (310) 274-7100

dellis@ellisgeorge.com

*Counsel for Defendants L'Oréal USA, Inc.;
L'Oréal USA Products, Inc.; and SoftSheen-
Carson LLC*

EXHIBIT A

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF ILLINOIS
EASTERN DIVISION**

IN RE: HAIR RELAXER MARKETING
SALES PRACTICES AND PRODUCTS
LIABILITY LITIGATION

MDL No. 3060

Master Docket No. 1:23-cv-00818

Hon. Mary M. Rowland

**SUPPLEMENTAL LETTER OF REQUEST FOR INTERNATIONAL JUDICIAL
ASSISTANCE REGARDING THE APPOINTMENT OF A COMMISSIONER
PURSUANT TO THE HAGUE CONVENTION OF 18 MARCH 1970 ON THE TAKING
OF EVIDENCE ABROAD IN CIVIL OR COMMERCIAL MATTERS**

A request is hereby made by the United States District Court for the Northern District of Illinois, at 219 South Dearborn Street, Chicago, Illinois 60604, UNITED STATES OF AMERICA, to the Ministère de la Justice, Direction des Affaires Civiles et du Sceau, Bureau de l'entraide civile et commerciale internationale (D3), 13, Place Vendôme, 75042 Paris Cedex 01, FRANCE, for additional assistance in obtaining document discovery from L'Oréal S.A., the French foreign parent of Defendants L'Oréal USA, Inc., L'Oréal USA Products, Inc. and SoftSheen-Carson LLC (collectively, "L'Oréal USA") in the above-captioned action. This request is made pursuant to Chapter II of the Hague Convention on the Taking of Evidence Abroad in Civil or Commercial Matters, March 18, 1970, T.I.A.S. No 7444, 28 U.S.T. 2555 (the "Hague Convention").

1. Sender

The Honorable Mary M. Rowland
United States District Court
Northern District of the State of Illinois
Eastern Division
Everett McKinley Dirksen United States
Courthouse
219 South Dearborn Street, Courtroom 1225
Chicago, IL 60604
United States of America

2. Central Authority of Requested State Ministère de la Justice
Direction des Affaires Civiles et du Sceau
Bureau de l'entraide civile et commerciale
(D3)
13, Place Vendôme
75042 Paris Cedex 01
France

3. Person to whom executed request is to be
returned Dennis S. Ellis
Ellis George LLP
2121 Avenue of the Stars, 30th Floor
Los Angeles, CA 90067
United States of America

L'Oréal USA also designates the appointed
Commissioner Noëlle Lenoir, to accept
service of the Hague Convention
authorization and notifications from the
French governmental authorities related to the
Hague Convention proceedings. The
Commissioner shall transmit such
authorization and notifications to counsel for
L'Oréal USA.

In conformity with Chapter II, Article 17 of the Hague Convention, the United States
District Court for the Northern District of Illinois presents its compliments to the Ministère de la
Justice and has the honor to submit the following request:

4. Specifications of the date by which the
requesting authority requires receipt of the
response to the Supplemental Request for
International Judicial Assistance
("Supplemental Request for Assistance") The requesting authority would greatly
appreciate a response to the Request for
Assistance within 21 days or as soon
thereafter as is practicable.

5. Requesting judicial authority The Honorable Mary M. Rowland
United States District Court Judge
Northern District of the State of Illinois
Eastern Division
Everett McKinley Dirksen United States
Courthouse
219 South Dearborn Street, Courtroom 1225
Chicago, IL 60604
United States of America

6. To the competent authority of The Republic of France
7. Name of the case and identifying number *IN RE: HAIR RELAXER MARKETING SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION*
MDL 3060
Master Docket No. 1:23-cv-00818 (N.D. Ill.)
8. Name of Plaintiffs Plaintiffs are women alleging that their use of hair relaxer products caused them to develop injuries, including uterine and ovarian cancer, and other injuries.
- Name and addresses of Plaintiffs' representatives
- Edward A. Wallace
WALLACE MILLER
150 N. Wacker Dr., Suite 1100
Chicago, Illinois 60606
T: (312) 261-6193
Plaintiffs' Liaison Counsel
- Diandra "Fu" Debrosse
DICELLO LEVITT LLP
505 20th Street North, Suite 1500
Birmingham, Alabama 35203
T: (312) 214-7900
Plaintiffs' Co-Lead Counsel
- Fidelma L. Fitzpatrick
MOTLEY RICE LLC
Providence, Rhode Island 02903
40 Westminster Street, Fifth Floor
T: (401) 457-7700
Plaintiffs' Co-Lead Counsel
- Michael A. London
DOUGLAS & LONDON, P.C.
59 Maiden Lane, Sixth Floor
New York, New York 10038
T: (212) 566-7500
Plaintiffs' Co-Lead Counsel
- Benjamin L. Crump
BEN CRUMP LAW FIRM
122 South Calhoun Street
Tallahassee, Florida 32301
T: (850) 224-2020

Plaintiffs' Co-Lead Counsel

9. Name of relevant Defendant

L'Oréal USA, Inc., L'Oréal USA Products, Inc. and SoftSheen-Carson LLC (collectively, "L'Oréal USA")

Name and address of relevant Defendant's representative

Dennis S. Ellis
Ellis George LLP
2121 Avenue of the Stars, 30th Floor
Los Angeles, CA 90067
United States of America

10. Nature and purpose of the proceedings and summary of the facts

On or around October 21, 2022, Plaintiffs began filing lawsuits across the country against manufacturers of hair relaxer products, including L'Oréal USA. On February 6, 2023, the Judicial Panel on Multidistrict Litigation created this MDL and assigned all of the federal cases to this Court.

On May 15, 2023, Plaintiffs filed a Master Long Form Personal Injury Complaint in the MDL (ECF No. 106), alleging that their regular and prolonged exposure to Defendants' hair relaxer products caused them to develop injuries, including uterine and ovarian cancer and other injuries. Based on these allegations, Plaintiffs asserted personal injury, wrongful death, misrepresentation, fraud, and consumer protection claims. The Defendants filed a motion to dismiss the Master Long Form Complaint. (ECF No. 142.) The Court granted the motion, in part, dismissing the fraud-based claims and denying the balance of the motion, allowing Plaintiffs to proceed with their products liability claims. (ECF No. 291.)

On December 5, 2024, the Court granted L'Oréal USA's Unopposed Motion for Issuance of a Letter of Request (ECF No. 973), finding it proper to issue a Request for International Judicial Assistance to authorize a commissioner in France to assist in the process of obtaining certain documents from

France that are responsive to discovery served by Plaintiffs in this action and subject to orders of this Court. Also on December 5, the Court issued a Letter of Request to the French Ministère de la Justice (ECF No. 974).

On December 17, 2024, the French Ministère de la Justice appointed Ms. Noëlle Lenoir as Commissioner in connection with the review of the categories of documents subject to the Court's prior orders.

Since that time, L'Oréal USA has produced documents in connection with the prior Letter of Request and the Plaintiffs, L'Oréal USA, and L'Oréal S.A. have met and conferred regarding the appropriate scope of discovery and additional documents (to the extent they exist) that Plaintiffs seek in the possession of L'Oréal S.A., including through conferences with the Special Master appointed by the Court in this action to assist in resolution of discovery disputes. As a result of this process, Plaintiffs, L'Oréal USA, and L'Oréal S.A. have agreed that additional categories of documents responsive to discovery requests served on L'Oréal USA shall be obtained from L'Oréal S.A.

11. Evidence to be obtained

On a rolling basis as needed, L'Oréal S.A. will provide to the Commissioner the documents that are the subject of the parties' agreement (identified in **Exhibit 1** attached hereto) (the "Supplemental Documents"), for transmission by the Commissioner to L'Oréal USA for review and production in this action. L'Oréal USA must produce responsive documents that are in the possession of L'Oréal S.A. and that are identified in Exhibit 1 attached hereto.

12. Documents or other property to be inspected

L'Oréal USA objected to Plaintiffs' Requests for Production to the extent they sought documents from sources other than L'Oréal USA, but the Court overruled those objections. L'Oréal USA is now producing the documents.

13. Whether the Plaintiffs or Defendant have consented to document discovery

14. Suggested date by which any document discovery must be completed

L'Oréal S.A.'s initial transmission of the Supplemental Documents to the Commissioner will occur within 21 days after the Ministère de la Justice's approval of the Court's Supplemental Request for Assistance and expansion of the Commissioner's scope. L'Oréal S.A. will transmit any remaining Supplemental Documents to the Commissioner on a rolling basis.

15. Special methods or procedure to be followed

L'Oréal S.A. will transmit the Supplemental Documents to the Commissioner who will then transmit the Supplemental Documents to L'Oréal USA for review and production in this action.

The Commissioner's sole duty with respect to the Supplemental Documents is to receive them from L'Oréal S.A. and transmit them to L'Oréal USA. In receiving the Supplemental Documents from L'Oréal S.A., the Commissioner may review the Supplemental Documents only to ensure that the Supplemental Documents correspond to the categories and requests described in Exhibit 1. The Commissioner shall not review the Supplemental Documents for relevance, privilege or any other reason, and the Commissioner shall not, on her own, make any decision to limit the Supplemental Documents received by L'Oréal S.A. Should the Commissioner have concerns about a particular document she receives from L'Oréal S.A., she shall contact L'Oréal S.A. to address/resolve any such concern(s).

16. Specification of privilege or duty to refuse to produce documents under the law of the State of origin

Neither this Request for Assistance nor the transmission of Supplemental Documents by L'Oréal S.A. to the Commissioner pursuant to the Hague Convention, shall waive, or be deemed or argued to have waived, any argument, position, objection, allegation or claim or defense of Plaintiffs or L'Oréal USA, or any defense to personal jurisdiction that L'Oréal S.A. may otherwise have, or of the attorney-client privilege, the work product

doctrine, or any other privileges, rights, protections or prohibitions that may apply to that evidence under the law of France, the United States, or the State of Illinois.

17. Authority appointing Commissioner, pending approval of the Ministère de la Justice

United States District Court
Northern District of the State of Illinois
Eastern Division
Everett McKinley Dirksen United States
Courthouse
219 South Dearborn Street, Courtroom 1225
Chicago, IL 60604
United States of America

18. Commissioner

Ms. Noëlle Lenoir
nlenoir@noellelenoir-avocats.com
Attached as **Exhibit 1** hereto is the Order of the United States District Court for the Northern District of Illinois, regarding expanding the scope of Ms. Noëlle Lenoir's appointment as Commissioner, pending the approval of the Ministère de la Justice.

19. Costs

All costs of this Hague Convention process, including, without limitation, the fees of the Commissioner, translation fees for these motion papers, and any transmittal costs for the Supplemental Documents, will be borne by L'Oréal USA. Each party will be responsible for the fees and expenses, if any, of its own attorneys relating to any proceedings arising from this Hague Convention process.

This Court expresses its appreciation to the Ministère de la Justice for its courtesy and assistance in this matter.

Dated:

Hon. Mary M. Rowland
United States District Court Judge

EXHIBIT 1

Date Served	Set	RFP	Request
6/27/2023	1	8	REQUEST NO. 8. ALL Corrective Action Plans or Procedures (“CAPs” or “CAPAs”), undertaken with respect to YOUR HAIR RELAXER PRODUCT(S).
6/27/2023	1	9	REQUEST NO. 9. ALL drafts and final versions of policies, procedures, standard operating procedures, and/or protocols for or relevant to the (1) manufacture, (2) testing, (3) quality assurance, (4) risk assessment, (5) clinical assessments, (6) regulatory activities, (7) communications with regulatory agencies, (8) product safety, (9) toxicology, (10) labeling, (11) distribution, (12) production, (13) packaging, (14) sale, (15) publication planning, (16) storage, (17) communications with private individuals or entities regarding safety, and (18) LABEL changes (19) research and development (20) product formulation and (21) collection, analysis and reporting of adverse events with regard to YOUR HAIR RELAXER PRODUCT(S).
6/27/2023	1	10	REQUEST NO. 10. Produce all published and unpublished studies or laboratory and animal testing YOU conducted concerning the safety of YOUR HAIR RELAXER PRODUCT(S) whether proposed, pending, and/or completed. This request includes, but is not limited to, DOCUMENTS and COMMUNICATIONS regarding the following: 1. Trial protocols and testing protocols, and any amendments thereto; 2. Laboratory notebooks; 3. Raw data; 4. Data summaries and/or analysis; 5. Test results, including any summaries and/or analyses; 6. Draft and final reports, whether or not submitted to the FDA or other regulatory agency; 7. Draft and published results, articles, posters, abstracts, white papers, position papers, and presentations of testing data; 8. Internal memoranda or COMMUNICATIONS concerning studies or results; 9. Summaries or compilations of medical literature relating or referring to YOUR HAIR RELAXER PRODUCT(S); 10. Comparisons or data summaries relating or referring to YOUR HAIR RELAXER PRODUCT(S); and 11. ALL internal or external COMMUNICATIONS relating or referring to any STUDY relating to a HAIR RELAXER PRODUCT(S) that involves or mentions hormone-sensitive cancers.

Date Served	Set	RFP	Request
6/27/2023	1	11	REQUEST NO. 11. ALL scientific journal articles submitted to any academic or scientific publication, written or drafted in whole, or in part, by YOU, YOUR EMPLOYEES or scientists or third parties who received funding or other forms of compensation from YOU or other entities retained or owned (wholly or in part) by YOU, regarding any HAIR RELAXER PRODUCT(S).
6/27/2023	1	13	REQUEST NO. 13. ALL DOCUMENT retention or destruction policies for the period of time YOU or other entities retained or owned (wholly or in part) by YOU, manufactured, sold, distributed, or licensed any HAIR RELAXER PRODUCT(S) until present.
6/27/2023	1	14	REQUEST NO. 14. ALL litigation hold / preservation letters issued or received by YOU, or other entities retained or owned (wholly or in part) by YOU, relating or referring to any HAIR RELAXER PRODUCT(S).
6/27/2023	1	15	REQUEST NO. 15. ALL Patents and Patent Applications for YOUR HAIR RELAXER PRODUCT(S).
6/27/2023	1	16	REQUEST NO. 16. ALL Meeting Minutes and/or Presentations by or to YOUR Board of Directors concerning the following: 1. The Safety of YOUR HAIR RELAXER PRODUCT(S). 2. LABEL Changes for YOUR HAIR RELAXER PRODUCT(S). 3. Regulatory actions concerning YOUR HAIR RELAXER PRODUCT(S). 4. Warnings concerning the safety of YOUR HAIR RELAXER PRODUCT(S). 5. Scientific Studies concerning the potential health effects of YOUR HAIR RELAXER PRODUCT(S). 6. Consumer Concerns or Complaints related to YOUR HAIR RELAXER PRODUCT(S) 7. Analysis of the market share and/or increase or decrease of market share for YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	2	1	REQUEST NO. 1. To the extent YOU conduct or have conducted business relating to the manufacture, distribution, or marketing of any HAIR RELAXER PRODUCT(S) with any other DEFENDANT in this ACTION, please produce DOCUMENTS, including contracts, agreements (including but not limited to indemnification agreements), invoices, payment records, and communications, demonstrating the nature, extent, and length of this business relationship.

Date Served	Set	RFP	Request
12/1/2023	2	2	REQUEST NO. 2. ALL DOCUMENTS relating or referring to any licenses, contracts, royalty arrangements or other agreements made by YOU, and any other entity relating to the development, sale, marketing, manufacturing, testing, or compliance with any regulations for any HAIR RELAXER PRODUCT(S).
12/1/2023	2	4	REQUEST NO. 4. ALL DOCUMENTS relating or referring to any Asset Purchase Agreement between YOU and any entity relating to any HAIR RELAXER PRODUCT(S) and liabilities for any HAIR RELAXER PRODUCT(S) subsequent to an Asset Purchase Agreement.
12/1/2023	2	5	REQUEST NO. 5. ALL DOCUMENTS relating or referring to any agreement concerning any supplier agreement for YOUR HAIR RELAXER PRODUCT(S), including, but not limited to the supply of raw materials and/or ingredients, the identity, location, and time frames for each.
12/1/2023	2	7	REQUEST NO. 7. ALL DOCUMENTS, including photographs and/or video recordings, regarding or relating to any testing or inspections of the equipment utilized in the manufacturing of YOUR HAIR RELAXER PRODUCT(S), including any third party that conducted and/or was otherwise involved in the testing or inspections of the equipment utilized in the manufacturing of YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	2	8	REQUEST NO. 8. ALL DOCUMENTS identifying fragrance components used in YOUR HAIR RELAXER PRODUCT(S) and the exact chemical content of each fragrance.
12/1/2023	2	9	REQUEST NO. 9. ALL DOCUMENTS concerning suppliers of raw materials and/or ingredients for YOUR HAIR RELAXER PRODUCT(S). See www.loreal-finance.com/system/files/2023-03/LOREAL_2022_Universal_Registration_Document_en.pdf (p. 133) (last visited December 1, 2023).
12/1/2023	3	1	REQUEST NO. 1 ALL DOCUMENTS and COMMUNICATIONS relating or referring to communications to or among the Board of Directors or other company controlling group, relating or referring to HAIR RELAXER PRODUCTS, including but not limited to the design, formulation, testing, marketing, sale, or promotion of HAIR RELAXER PRODUCTS.

Date Served	Set	RFP	Request
12/1/2023	3		REQUEST NO. 2. ALL DOCUMENTS and COMMUNICATIONS identifying any and all third parties responsible for or involved in any aspect of YOUR HAIR RELAXER PRODUCT(S), including, but not limited to the manufacture, testing, quality assurance, sourcing, supply chain, risk assessment, product and ingredient monitoring, medical and clinical assessments, regulatory activities, communications with regulatory agencies, distribution, production, packaging, labeling, sale, marketing, and publication for YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	3		REQUEST NO. 3. ALL DOCUMENTS and COMMUNICATIONS between or among YOU and any other named DEFENDANT in this Action or HAIR RELAXER PRODUCT manufacturer, supplier, distributor, or retailer relating or referring to any HAIR RELAXER PRODUCT(S) and (1) hormone-sensitive cancers, (2) safety, (3) risk assessments, (4) clinical assessments, (5) communications with regulatory agencies, (6) recalls or market withdrawals, (7) sales numbers, or (8) pricing.
12/1/2023	3		REQUEST NO. 5. ALL statements, whether internal or external, and drafts thereof, issued by YOU regarding any actual or proposed safety warnings, label changes, recall (or nonrecall), or market withdrawal (or non-withdrawal) of any HAIR RELAXER PRODUCT(S).
45261	3		REQUEST NO. 6. ALL DOCUMENTS and COMMUNICATIONS relating or referring to YOUR involvement in fraud, criminal or civil investigations, qui tam lawsuits, regulatory investigations, charges, fines, guilty pleas, Deferred Prosecution Agreements, Corporate Integrity Agreements, or litigation, including administrative or regulatory processes related to YOUR HAIR RELAXER PRODUCT(S) and/or the promotion or marketing thereof.
12/1/2023	3		REQUEST NO. 8. ALL DOCUMENTS and COMMUNICATIONS between YOU and the Personal Care Products Council (“PCPC”), formerly known as the Cosmetics, Toiletry and Fragrance Association (“CTFA”) related to any HAIR RELAXER PRODUCT(S).
12/1/2023	3		REQUEST NO. 9. ALL DOCUMENTS sufficient to identify the name, case caption, attorney and/or status of any personal injury lawsuit filed against YOU involving any HAIR RELAXER PRODUCT(S), including cases which have been dismissed, settled, withdrawn or tried to verdict.
12/1/2023	3		REQUEST NO. 11. ALL DOCUMENTS and COMMUNICATIONS relating or referring to communications to or among the Board of Directors or other company controlling group, relating or referring to the safety of HAIR RELAXER PRODUCTS.

Date Served	Set	RFP	Request
12/1/2023	4		REQUEST NO. 1. ALL strategic marketing plans and marketing strategy DOCUMENTS and COMMUNICATIONS related to YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	4		REQUEST NO. 2. ALL DOCUMENTS and COMMUNICATIONS relating or referring to analyses of the hair care and/or cosmetics market, YOUR competitors, and YOUR customers related to YOUR HAIR RELAXER PRODUCT(S), including, but not limited to SWOT analyses, PEST analyses, competitive analyses, and marketing segmentation analyses.
12/1/2023	4		REQUEST NO. 11. ALL DOCUMENTS and COMMUNICATIONS with YOU and any cosmetology school or cosmetic group relating or referring to any HAIR RELAXER PRODUCT(s) and/or the haircare or cosmetics market.
12/1/2023	4		REQUEST NO. 13. ALL DOCUMENTS and COMMUNICATIONS reflecting YOUR participation in and/or creation of unbranded and/or content marketing of hair care products.
12/1/2023	4		REQUEST NO. 16. ALL DOCUMENTS and COMMUNICATIONS relating or referring to YOUR use of social listening applications, web analytics, advertisements, geotargeting/fencing, and/or targeting in promoting and/or marketing YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	4		REQUEST NO. 19. ALL DOCUMENTS and COMMUNICATIONS relating or referring to drafts and final versions of policies, procedures, standard operating procedures, and/or protocols related to the (1) marketing; (2) communications; (3) public relations; (4) media relations; and (5) advertising with regard to YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	5		REQUEST NO. 1. ALL DOCUMENTS and COMMUNICATIONS relating or referring to the master formulary for YOUR HAIR RELAXER PRODUCT(S) and any formulation changes.
12/1/2023	5		REQUEST NO. 2. ALL DOCUMENTS and COMMUNICATIONS relating or referring to the manufacture, formulation, or compounding of YOUR HAIR RELAXER PRODUCT(S), including but not limited to all master batch records, representative batch records, master formularies, contracts, orders, specifications, or analytical tests and analytical test methods relating to the manufacture, formulation, compounding or packaging of YOUR HAIR RELAXER PRODUCT(S), or any chemical components thereof.

Date Served	Set	RFP	Request
12/1/2023	5		REQUEST NO. 3. ALL DOCUMENTS and COMMUNICATIONS relating or referring to the safety or health risks associated with YOUR HAIR RELAXER PRODUCT(S), any components and constituents thereof, or any contaminants or impurities that may result from the manufacture, formulation, compounding, or packaging of YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	5		REQUEST NO. 4. ALL DOCUMENTS and COMMUNICATIONS relating or referring to the components of each of YOUR HAIR RELAXER PRODUCTS, including specific chemicals, chemical substances, compounds and compound formulations, solvents, emulsifiers, biologics (identified by chemical composition or DNA sequence) the exact and actual concentrations of each chemical (not percentages), the specific isomeric form of each chemical and compound, and the source of such components and their tradenames and grades.
12/1/2023	5		REQUEST NO. 5. ALL DOCUMENTS and COMMUNICATIONS relating or referring to the design or chemical composition of YOUR HAIR RELAXER PRODUCT(S), including any actual or contemplated changes to the design or chemical composition of such products.
12/1/2023	5		REQUEST NO. 6. ALL DOCUMENTS and COMMUNICATIONS relating or referring to any meetings among YOU concerning the development or testing of YOUR HAIR RELAXER PRODUCT(S), including but not limited to: a. Timelines; b. Projections; c. Presentations; d. Project team meeting minutes and agendas; e. Phone and meeting notes; f. Evaluations; g. Locations of Manufacturer; h. Sources of Chemical Components; i. Data compilations; and j. Competitive analyses.
12/1/2023	5		REQUEST NO. 7. ALL DOCUMENTS and COMMUNICATIONS regarding whether to conduct epidemiological or other types of scientific studies to determine if any HAIR RELAXER PRODUCT may cause or is associated with hormone-sensitive cancers, hormonal alterations, immunological changes, or other human health effects, risks, or hazards.

Date Served	Set	RFP	Request
12/1/2023	5		REQUEST NO. 8. ALL DOCUMENTS and COMMUNICATIONS relating or referring to any contracts, agreements, memoranda, and payment or expense records, with regard to any attempt by YOU to retain, engage or otherwise provide financial support or item of value to any person (or to a nonprofit, charity or LLC owned in whole or in part by that person), including any persons in any scientific discipline, with regard to any proposed or actual study, assessment, evaluation and/or analysis of the safety, impurity, contamination, or chemical content of YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	5		REQUEST NO. 9. ALL DOCUMENTS and COMMUNICATIONS relating or referring to interactions with external consultants or third parties regarding the development and testing of YOUR HAIR RELAXER PRODUCT(S), including but not limited to agendas, meeting minutes, data compilations, and presentations.
12/1/2023	5		REQUEST NO. 10. ALL DOCUMENTS and COMMUNICATIONS relating or referring to the development, testing, manufacturing, packaging, and/or performance of stability reports of YOUR HAIR RELAXER PRODUCT(S) performed by YOU.
12/1/2023	5		REQUEST NO. 11. ALL DOCUMENTS and COMMUNICATIONS concerning the ability of a user to follow or not-follow the Instructions for the Use of YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	5		REQUEST NO. 12. ALL DOCUMENTS referring to or discussing recommendations from the International Fragrance Association, the Scientific Committee on Consumer Safety or any other trade, research, or scientific group about use of EDCs, in combination or isolation, in cosmetic productions and in rinse-off versus leave-on cosmetic products.
12/1/2023	5		REQUEST NO. 13. ALL DOCUMENTS and COMMUNICATIONS relating to any testing, whether considered or performed, to evaluate the interaction between ingredients used in YOUR HAIR RELAXER PRODUCT(S), and/or interactions between YOUR HAIR RELAXER PRODUCT(S) and any other hair care product YOU anticipated consumers would use with YOUR HAIR RELAXER PRODUCT(S) and ingredients that were considered for removal as a result.

Date Served	Set	RFP	Request
12/1/2023	5		REQUEST NO. 14. ALL DOCUMENTS and COMMUNICATIONS relating to testing of YOUR HAIR RELAXER PRODUCT(S) by third parties including, but not limited to: Aster, Doctor Laine, Safepharm, Hazelton Lyon, Foundation Rothschild, Pharmaco LSR, Immuno Teratotoxicologie, Aldridge ROA MD, CIT, CiToxLab, TNO Chemistry, Peritesco, Chares River Evic., Institut D'Expertise, RCTS. Inc., SGS Harrison Research Laboratories, Inc., Harrison Research Laboratories, Inc., Consumer Product Testing Co., Syres, Intertek, Episkin, In Vitro International, and TRI Princeton Research Education Service.
12/1/2023	5		REQUEST NO. 15. ALL DOCUMENTS and COMMUNICATIONS relating to the article: Che-June Chang, et al., Use of Straighteners and Other Hair Products and Incident Uterine Cancer, 114 J. NAT'L CANCER INST. 12, 1636-45 (Dec. 2022).
12/1/2023	5		REQUEST NO. 16. ALL DOCUMENTS and COMMUNICATIONS relating to the article: Alexandra White, et al., Use of hair products in relation to ovarian cancer risk, 42 CARCINOGENESIS 9, 1189-95 (Oct. 2021).
12/1/2023	5		REQUEST NO. 18. ALL DOCUMENTS and COMMUNICATIONS related to historic samples of YOUR HAIR RELAXER PRODUCT(S) and their location, all labels used on the products (both past and present), all customer complaint records and databases, all instructions for use for each product (both past and present), all records of purported customer injury from the products, all images maintained of all YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	5		REQUEST NO. 19. ALL DOCUMENTS and COMMUNICATIONS relating or referring to research performed by YOU or any third-party regarding ingredients in YOUR HAIR RELAXER PRODUCT(S) found in the ingredient catalogue prepared by YOU to comply with the European Parliament's proposed REACH project.
12/1/2023	5		REQUEST NO. 20. ALL DOCUMENTS and COMMUNICATIONS relating to the quality, safety, and testing included in the "4 step" evaluation ¹ of YOUR HAIR RELAXER PRODUCT(S), including but not limited to policies and procedures, ingredient hazard potentials, ingredient origins, ingredient identity cards, conditions and frequency of use analysis, ingredient dosage, maximum safe concentrations, microbiological analyses, raw materials quality, tolerance verifications, toxicologist reports, approval visas for marketing, quality control testing, and post marketing surveillance.

Date Served	Set	RFP	Request
12/1/2023	5		REUQEST NO. 21. ALL DOCUMENTS and COMMUNICATIONS relating or referring to research performed by YOU or any third parties regarding endocrine-disrupting chemicals, modulation, and endocrine disruption as described on YOUR webpage titled 'What is an endocrine disruptor,' including without limitation, research performed by Dr. Patrick Balaguer from the National Institute of Health and Medical Research (INSERM, Montpellier) or through the FEATS project in partnership with the National Institute of Industrial Environment and Risks (INERIS) and the European ERGO project
12/1/2023	5		REQUEST NO. 22. ALL DOCUMENTS and COMMUNICATIONS relating to the development of YOUR "policy of transparency in fragrances," including any testing and analysis performed by YOU or with MANE, IFF, Givaudan, Firmenich, or any other external consultants or entities.3
12/1/2023	5		REQUEST NO. 23. All DOCUMENTS and COMMUNICATIONS identifying any ingredients that were removed or were evaluated for removal from YOUR HAIR RELAXER PRODUCT(S) because of concerns about the ingredients' potential interaction with the product user's hormonal system, and any assessments, memorandum, testing and/or evaluations related to said evaluation(s).4
12/1/2023	5		REQUEST NO. 24. All DOCUMENTS and COMMUNICATIONS identifying the chemical names, common names or synonyms, Chemical Abstract Service (CAS) number, and other unique identifiers, impurities, and stabilizing additives for YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	5		REQUEST NO. 25. All DOCUMENTS and COMMUNICATIONS relating to any testing, evaluation, analysis and identification of any chemical listed as an endocrine disruptor by the World Health Organization in YOUR HAIR RELAXER PRODUCT(S) or as a byproduct from the use of said PRODUCT, either alone or in combination with any other chemicals, ingredients, or finished products reasonably anticipated to be used at or near the time of Hair Relaxer Product use.

Date Served	Set	RFP	Request
12/1/2023	5		REQUEST NO. 26. All DOCUMENTS and COMMUNICATIONS relating to any testing, evaluation, analysis and identification of any chemical contained in YOUR HAIR RELAXER PRODUCT(S) and/or PRODUCT formulations, whether marketed or not, that are identified in the National Toxicology Program (NTP) Report on Carcinogens (latest edition) or found to be a potential carcinogen in the International Agency for Research on Cancer (IARC) Monographs, by OSHA or by the U. S. Food and Drug Association and/or any other relevant regulatory body.
12/1/2023	5		REQUEST NO. 27. All DOCUMENTS and COMMUNICATIONS relating to the “platform of predictive tests to ensure the safety” of consumers using YOUR HAIR RELAXER PRODUCT(S).5
12/1/2023	5		REQUEST NO. 28. All DOCUMENTS and COMMUNICATIONS relating to Charles Bouillon and John Wilkinson, The Science of Hair Care, (Taylor & Francis, 2d ed., 2005) (“The Science of Hair Care”), Chapter 6: Permanent Waving and Hair Straightening, Chapter 11: Hair Product Safety, Chapter 13: The Regulation of Cosmetic Products, Chapter 15: Adverse Reactions to Hair Products, and Chapter 16: Occupational Disorders in Hairdressers, including underlying research and data, drafts, and unpublished chapters or sections.
12/1/2023	5		REQUEST NO. 29. All DOCUMENTS and COMMUNICATIONS relating to any analysis and testing performed by You or any third parties retained by You to evaluate the potential health risks associated with the use of YOUR HAIR RELAXER PRODUCT(S), and chemicals and ingredients used in Hair Relaxer Products, including “...(a) [the chemical’s] toxicity, (b) the potential human systemic exposure and (c) the dose-response of the relevant toxic effect, the toxicologic potential of a substance is only relevant when significant human systemic exposure occurs.” See The Science of Hair Care, Chapter 4, section 4.4.3. Human Exposure to Oxidative Hair Dye Ingredients, p. 353.
12/1/2023	5		REQUEST NO. 30. All DOCUMENTS and COMMUNICATIONS concerning any testing or study evaluating YOUR HAIR RELAXER PRODUCT(S), and/or the chemicals and ingredients used in Your Hair Relaxer Products, for the presence of any chemical listed in The Science of Hair Care, Chapter 4, Toxicology of Hair Dyes, Tables 2 through 9.
12/1/2023	5		REQUEST NO. 31. ALL DOCUMENTS and COMMUNICATIONS relating to the article: Bertrand KA, et al. Hair relaxer use and risk of uterine cancer in the Black Women’s Health Study. Environ Res. 2023 Dec 15;239(Pt 1):117228. doi: 10.1016/j.envres.2023.117228. Epub 2023 Oct 10. PMID: 37821068.

Date Served	Set	RFP	Request
45261	5		REQUEST NO. 32. All DOCUMENTS and COMMUNICATION relating to any testing, whether considered or performed, to evaluate the interaction between ingredients used in YOUR HAIR RELAXER PRODUCT(S), and/or interactions between YOUR HAIR RELAXER PRODUCT(S), and any other hair care product YOU anticipated consumers would use with YOUR HAIR RELAXER PRODUCT(S), or YOU marketed to consumers for use with YOUR HAIR RELAXER PRODUCT(S), including testing to evaluate potential byproducts of said interactions and their potential to cause modulation or endocrine disruption or to interact with the product user's hormonal system. ⁶
12/1/2023	5		REQUEST NO. 33. ALL DOCUMENTS and COMMUNICATIONS relating to any and all safety dossiers, safety visas, safety authorizations, and/or safety attestations, and any underlying data collected or reviewed in furtherance of same, for the raw materials in YOUR HAIR RELAXER PRODUCT(S) and/or for the finished products. See e.g., LOUSA-0003995-LOUSA-0004015.
12/1/2023	5		REQUEST NO. 34 ALL DOCUMENTS and COMMUNICATIONS stored in the following programs, Expertise, Safe'IT, D2Tox, ClaimsNet, Safety Assistant/NRCE Safety Assit, Milor, FormulaNET and/or Formulation Center relating or referring to HAIR RELAXER PRODUCTS.
12/1/2023	5		REQUEST NO. 35. ALL DOCUMENTS and COMMUNICATIONS, including every agenda, memoranda, presentation, and agreement, relating to the International Symposiums on Ethnic Hair and Skin sponsored by L'Oréal's Institute for Ethnic Hair and Skin Research regarding relaxing hair or YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	5		REQUEST NO. 36. ALL DOCUMENTS and COMMUNICATIONS relating to any due diligence performed by YOU or on YOUR behalf related to Your acquisition of SoftSheen Products, Inc. and Carson, Inc. relating to their HAIR RELAXER PRODUCT(S).
12/1/2023	5		REQUEST NO. 37. ALL DOCUMENTS and COMMUNICATIONS relating to L'ORÉAL entering the ethnic category, including the purchase of SoftSheen Products, Inc. and Carson Inc., the involvement of those companies' employees in YOUR ethnic category work, research objectives, sales objectives and/or projections, and financial performance and sales documents since.

Date Served	Set	RFP	Request
12/1/2023	5		<p>REQUEST NO. 39. ALL DOCUMENTS and COMMUNICATIONS relating to the development, manufacture, testing, sale, distribution, and post-market surveillance for YOUR HAIR RELAXER PRODUCT(S) including but not limited to DOCUMENTS and COMMUNICATIONS prepared by or received by the following divisions, departments, and/or groups:</p> <ol style="list-style-type: none"> 1. Consumer Product Division (“CPD”); 2. Professional Product Division (“PPD”); 3. Active Cosmetic Division (“ACD”); 4. Next Big Brands (“NBB”); 5. Consumer Markets Intelligence (“CMI”); 6. Division de Market International (“DMI”); 7. Research & Innovation (“R&I”); 8. Sourcing Team; 9. Safety, Regulatory Claims, Microbiology (“SRCM”); 10. Consumer Complaints Division; 11. Corporate Responsibility Division; 12. Claims Substantiation (work group within R&I); 13. Digital Transformation (group within R&I); 14. Evaluation and Intelligence; 15. Safety Validation; and 16. Scientific Advisory Board; and 17. Open Development.
12/1/2023	6		<p>REQUEST NO. 2. ALL DOCUMENTS and COMMUNICATIONS with any consumer, advocacy groups, government agency, regulatory agency, or any third-party as to whether the labeling for YOUR HAIR RELAXER PRODUCT(S) was in compliance with any and all requirements.</p>
12/1/2023	6		<p>REQUEST NO. 3. ALL DOCUMENTS and COMMUNICATIONS concerning the European Commission’s European Cosmetics Regulation identification of 28 substances suspected of being endocrine disruptors, EDC, or other harmful chemicals, including Your consideration of same, including DOCUMENTS and COMMUNICATIONS relating to which of YOUR HAIR RELAXER PRODUCT(S), if any, contain(ed) one or more of the above referenced 28 substances.</p>

Date Served	Set	RFP	Request
12/1/2023	6		REQUEST NO. 4. ALL DOCUMENTS and COMMUNICATIONS relating to any complaints or third-party communications to or from any regulatory agency with regard to hormone-sensitive cancers and YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	6		REQUEST NO. 5. ALL DOCUMENTS relating to COMMUNICATIONS between YOU and any regulatory or health authorities regarding any of YOUR HAIR RELAXER PRODUCT(S) and cancers or any other injury potentially and/or alleged to be caused by YOUR HAIR RELAXER PRODUCT(S) or any other HAIR RELAXER PRODUCT(S).
12/1/2023	6		REQUEST NO. 6. ALL DOCUMENTS relating to root cause analysis procedures for HAIR RELAXER PRODUCT(S).
12/1/2023	6		REQUEST NO. 7. ALL DOCUMENTS and COMMUNICATIONS relating or referring to any information, complaints, or questions from any user of any HAIR RELAXER PRODUCT concerning any HAIR RELAXER PRODUCT including but not limited to, e-mails, meeting minutes, and general correspondences.

Date Served	Set	RFP	Request
12/1/2023	6		<p>REQUEST NO. 8. ALL DOCUMENTS and COMMUNICATIONS relating or referring to any post-marketing surveillance activities involving YOUR HAIR RELAXER PRODUCT(S), including but not limited to:</p> <ol style="list-style-type: none"> 1. Any causality assessments submitted to foreign regulatory agencies; 2. Periodic regulatory submissions regarding adverse events; 3. Periodic Benefit-Risk Evaluation Reports; 4. Safety Evaluation and Risk Management meetings; 5. Safety Review Team meetings; 6. Company Core Data Sheets; 7. Company Core Safety Information Sheets; 8. Material Safety Data Sheets; 9. Safety Data Sheets; 10. Justification Documents; 11. Any and all protocols relating to adverse event adjudication and reporting; 12. The evaluation or adjudication of adverse events; 13. Any compilations or analyses of adverse events; 14. Safety Signal Review or Analyses; 15. Risk Assessments; 16. Hazard Assessments; 17. Audits
12/1/2023	6		<p>REQUEST NO. 9. ALL DOCUMENTS and COMMUNICATIONS relating or referring to literature, including but not limited to medical literature, journals, abstracts, concerning hormone-sensitive cancers or any other injury potentially caused by HAIR RELAXER PRODUCT(S).</p>
12/1/2023	6		<p>REQUEST NO. 10. ALL DOCUMENTS and COMMUNICATIONS relating to the postmarket surveillance performed by YOU relating to YOUR HAIR RELAXER PRODUCT(S), including but not limited to YOUR International Cosmetic Safety Monitoring Network and reports from consumers and healthcare providers.</p>

Date Served	Set	RFP	Request
12/1/2023	6		<p>REQUEST NO. 13. ALL DOCUMENTS and COMMUNICATIONS relating to product labeling for YOUR HAIR RELAXER PRODUCT(S) including drafts and revisions thereto, including but not limited to:</p> <ol style="list-style-type: none"> 1. All final labels for YOUR HAIR RELAXER PRODUCT; 2. All draft labels for YOUR HAIR RELAXER PRODUCT; 3. All proposed labels submitted to the FDA or any other regulatory body that contained any warning or disclosure relating to hormone-sensitive cancers; 4. All DOCUMENTS or COMMUNICATIONS relating to any labeling, warning or risk pertaining to HAIR RELAXER PRODUCT(S); 5. All DOCUMENTS and communications relating or referring to the Company Core Data Sheet for YOUR HAIR RELAXER PRODUCT(S), including any drafts and revisions thereto;
12/1/2023	6		<p>REQUEST NO. 14. ALL DOCUMENTS and COMMUNICATIONS, including transcripts, notes, presentations, slides, memoranda, or other documentation of any hearings, proceedings, or meetings at the offices of and/or with any regulatory agency or health authorities regarding the safety of YOUR HAIR RELAXER PRODUCT(S) as well as any DOCUMENTS and COMMUNICATIONS made in preparation for the hearings, proceedings, or meetings at the offices of and/or with any regulatory agency or health authorities.</p>
12/1/2023	6		<p>REQUEST NO. 15. ALL DOCUMENTS and COMMUNICATIONS, including all agreements to engage any third party to represent your interests before any regulatory body regarding YOUR HAIR RELAXER PRODUCT(S).</p>
12/1/2023	6		<p>REQUEST NO. 24. ALL DOCUMENTS and COMMUNICATIONS relating to DAISY content related to YOUR HAIR RELAXER PRODUCT(S), whether originated from reports by suppliers, consumers, physicians, pharmacists, or others, including all case safety reports; the contents of all relevant fields in DAISY (including medical literature and studies) related to YOUR HAIR RELAXER PRODUCT(S) (see, e.g.. LOUSA-0003849 of L'Oréal Powerpoint presentation "Some General Rules for FSE Request & List of Toxicologists").</p>
12/1/2023	6		<p>REQUEST NO. 34. ALL DOCUMENTS and COMMUNICATIONS, including all reports, presentations, PowerPoints, memoranda, and emails, regarding Formulation Center content related to YOUR HAIR RELAXER PRODUCT(S).</p>

Date Served	Set	RFP	Request
12/1/2023	6		REQUEST NO. 37. ALL DOCUMENTS and COMMUNICATIONS, including all reports, presentations, PowerPoints, memoranda, and emails, regarding Legil'Or content related to YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	6		REQUEST NO. 40. ALL DOCUMENTS and COMMUNICATIONS, including all reports, presentations, PowerPoints, memoranda, and emails, regarding Magellan content related to YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	6		REQUEST NO. 43. ALL DOCUMENTS and COMMUNICATIONS, including all reports, presentations, PowerPoints, memoranda, and emails, regarding Compass content related to YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	6		REQUEST NO. 49. ALL DOCUMENTS and COMMUNICATIONS, including all reports, presentations, PowerPoints, memoranda, and emails, regarding Esko content related to YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	6		REQUEST NO. 52. ALL DOCUMENTS and COMMUNICATIONS stored in Legilor relating or referring to HAIR RELAXER PRODUCTS.
12/1/2023	7		REQUEST NO. 1. For each year YOU sold or obtained revenue for any HAIR RELAXER PRODUCT(S), produce ALL DOCUMENTS showing projected and actual sales, revenue, gross and net profits of any HAIR RELAXER PRODUCT(S) in the United States and territories on a monthly basis, by state/territory, to any purchaser, including but not limited to wholesalers, distributors, retailers and others. Provide: <ol style="list-style-type: none"> 1. Specific HAIR RELAXER PRODUCT(S) name; 2. Product size and configuration if variations exist; 3. Batch number; 4. Lot number; 5. Manufacturing code; 6. Names of customers to whom the product was shipped; 7. Quantities shipped to each customer; and 8. Shipping documents for each shipment.
12/1/2023	7		REQUEST NO. 2. ALL DOCUMENTS relating to or referring to business plans, projections or analyses of market share (domestically and globally) for any YOUR HAIR RELAXER PRODUCT(S).

Date Served	Set	RFP	Request
12/1/2023	7		REQUEST NO. 5. ALL DOCUMENTS relating to any analysis, projections, and/or forecasts done by YOU or on YOUR behalf regarding the impact or potential impact of cancer on the sales of YOUR HAIR RELAXER PRODUCT(S) and/or the impact or potential impact of the discontinuance of YOUR HAIR RELAXER PRODUCT(S).
12/1/2023	7		REQUEST NO. 10. ALL DOCUMENTS and COMMUNICATIONS that would affect the right to sell any HAIR RELAXER PRODUCT, including any merger agreements, acquisition, co-promotion agreement, or license that would have involved the transfer of control over any HAIR RELAXER PRODUCT trademark.
12/1/2023	7		REQUEST NO. 11. ALL DOCUMENTS and COMMUNICATIONS provided by YOU to any purchaser of YOUR HAIR RELAXER PRODUCTS, including but not limited to wholesalers, distributors, retailers and others, regarding policies, procedures, and/or specifications for the shipping, storage, transportation and distribution of YOUR HAIR RELAXER PRODUCT(S),

EXHIBIT B

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF ILLINOIS
EASTERN DIVISION**

IN RE: HAIR RELAXER MARKETING
SALES PRACTICES AND PRODUCTS
LIABILITY LITIGATION

MDL No. 3060

Master Docket No. 1:23-cv-00818

Hon. Mary M. Rowland

**[PROPOSED] ORDER GRANTING L'ORÉAL USA'S UNOPPOSED MOTION FOR
ISSUANCE OF SUPPLEMENTAL REQUEST FOR INTERNATIONAL JUDICIAL
ASSISTANCE, APPOINTMENT OF COMMISSIONER AND DIRECTION OF
SUBMISSION OF HAGUE CONVENTION APPLICATION**

The Court, having reviewed Defendant L'Oréal USA's Unopposed Motion for Issuance of Supplemental Request for International Judicial Assistance, Appointment of Commissioner and Direction of Submission of Hague Convention Application (the "Motion") and the Declaration of Dennis S. Ellis ("Supplemental Ellis Declaration") dated April 4, 2025, together with the exhibits annexed thereto in support of the Motion, and finding it proper to issue a Supplemental Request for International Judicial Assistance to authorize a Commissioner in France (the "Supplemental Request for Assistance") pursuant to 28 U.S.C. § 1781 and Chapter II of the Hague Convention on the Taking of Evidence Abroad in Civil or Commercial Matters, March 18, 1970, T.I.A.S. No 7444, 28 U.S.T. 2555 (the "Hague Convention"),

HEREBY ORDERS THAT:

1. The Motion is GRANTED.
2. The form of Supplemental Request for Assistance annexed to the Supplemental Ellis Declaration as **Exhibit A** is hereby issued as the Court's Request for Assistance and is fully incorporated herein.

3. Pursuant to Article 17 of the Hague Convention, Ms. Noëlle Lenoir, whose address is 28 Boulevard Raspail 75007 Paris, France (the “Commissioner”), is hereby duly appointed, pending the approval of the French Ministère de la Justice and subject to the terms of the Request for Assistance, as Commissioner to:

- a) receive additional documents from L’Oréal S.A. responsive to Plaintiffs’ Requests for Production of Documents directed to L’Oréal USA and that Plaintiffs, L’Oréal USA, and L’Oréal S.A. have stipulated will be produced (to the extent they exist), which consist of the categories of documents set forth in Exhibit 1 to the Supplemental Letter of Request (collectively, the “Supplemental Documents”);
- b) transmit the Supplemental Documents to L’Oréal USA for review and production in this action pursuant to Article 17 of the Hague Convention and in performance of her appointment as Commissioner and duties thereunder; and
- c) upon completion, inform the French Ministère de la Justice.

4. This signed Order and the signed Supplemental Request for Assistance will be given to Ellis George LLP, counsel for L’Oréal USA, which will file or request the Commissioner to file both documents and exhibits, along with French translations of both documents and exhibits, with the Ministère de la Justice, Direction des Affaires Civiles et du Sceau, Bureau de l’entraide civile et commerciale internationale (D3), 13, Place Vendôme, 75042 Paris Cedex 01, France.

5. This signed Order and the signed Supplemental Request for Assistance shall be filed with the Ministère de la Justice within ten (10) business days of their receipt. L’Oréal USA

will use its best efforts to promptly obtain the Ministère de la Justice's approval of the Court's Supplemental Request for Assistance and appointment of the Commissioner.

6. L'Oréal S.A.'s initial transmission of Supplemental Documents to the Commissioner will occur within 21 days after the Ministère de la Justice's approval of the Court's Supplemental Request for Assistance and appointment of the Commissioner. L'Oréal S.A. will transmit any remaining Supplemental Documents to the Commissioner on a rolling basis. Once L'Oréal S.A. informs the Commissioner that it has completed the transmission of Supplemental Documents, the Commissioner shall then transmit the Supplemental Documents to L'Oréal USA for review and production to Plaintiffs.

7. The Commissioner's sole duty with respect to the Supplemental Documents is to receive them from L'Oréal S.A. and transmit them to L'Oréal USA. In receiving the Supplemental Documents from L'Oréal S.A., the Commissioner may review the Supplemental Documents only to ensure that the Supplemental Documents correspond to the documents required pursuant to the stipulation and agreement of the parties embodied in Exhibit 1 to the Supplemental Letter of Requet. The Commissioner shall not review the Supplemental Documents for relevance, privilege or any other reason, and the Commissioner shall not, on her own, make any decision to limit the Supplemental Documents received by L'Oréal S.A. Should the Commissioner have concerns about a particular document it received from L'Oréal S.A., she shall contact L'Oréal S.A. to address/resolve any such concern(s).

8. Any unresolved disputes between L'Oréal USA and Plaintiffs regarding the production of the Supplemental Documents shall be determined exclusively by this Court. The Commissioner will adhere to any such order issued by this Court relating to document discovery in the above-captioned action.

9. Plaintiffs will not seek relief from this Court so long as the filing of this signed Order and the signed Request for Assistance with the Ministère de la Justice and transmission of the Supplemental Documents to the Commissioner occur within the timeframes set forth in paragraphs (5) – (6) above. Plaintiffs may seek relief from this Court, after first meeting-and-conferring in good faith with L'Oréal USA, if: (a) at any time, Plaintiffs fail to receive reasonable assurances from L'Oréal USA of its efforts promptly to seek approval of the Court's Supplemental Request for Assistance or the appointment of the Commissioner ; or (b) after approximately May 5, 2025 (unless otherwise extended by the consent of the parties), L'Oréal S.A. has not begun its transmission of the Supplemental Documents to the Commissioner for production, regardless of the cause for delay. L'Oréal USA will not object to a request by Plaintiffs for relief from this Court on the basis that this Motion was unopposed.

10. All costs of this Hague Convention process, including, without limitation, the fees of the Commissioner, translation fees for these motion papers, and any transmittal costs for the Supplemental Documents, will be borne by L'Oréal USA. Each party will be responsible for the fees and expenses, if any, of its own attorneys relating to any proceedings arising from this Hague Convention process.

11. Neither this Order nor the transmission of the Supplemental Documents by L'Oréal S.A. to the Commissioner pursuant to the Hague Convention shall constitute or operate as a waiver of any argument, position, objection, allegation or claim or defense of Plaintiffs or L'Oréal USA, or any defense to personal jurisdiction that L'Oréal S.A. may otherwise have, or of the attorney-client privilege, the work product doctrine, or any other privileges, rights, protections or prohibitions that may apply to that evidence under the law of France, the United States, or the State of Illinois. All materials withheld, in whole or in part, on the basis of

attorney-client privilege shall be so identified on an appropriate log in accordance with Federal Rule of Civil Procedure 26(b)(5).

12. Nothing in this Order precludes the potential expansion of the Commissioner's role by order of this Court, with respect to pending or future Court rulings or the agreement of the parties related to the further production of documents.

IT IS SO ORDERED.

Dated: _____

Hon. Mary M. Rowland
United States District Judge